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Ganfort is more cost effective than Duotrav and Xalacom in UK,
Denmark, Sweden, Norway, Finland, France, Italy and Spain.
Thus, the cost per percentage reduction in IOP is lower for
Ganfort compared to Duotrav and Xalacom.
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OBJECTIVES: To assess effectiveness, cost and cost-effectiveness
of Lucentis versus current medical practices in age relatedmacular
degenerescence in France. METHODS: A simulation decision
framework over 1-year time horizon compares a new speciﬁc
agent “Lucentis” versus usual care using two effectiveness end-
points: “vision acuity improvement rate” (greater than 15 letters
at the EDTRS scale) and “rate of legal blindness avoided”. The
two decision trees include various sequences of current therapies
and laser treatment, including or not Lucentis. Data sources come
from clinical data, literature and expert opinions for variability
and uncertainty assumptions. Probabilistic sensitivity analyses
were conducted taking into account speciﬁc distribution laws for
each cost and effectiveness parameters. French costing data
include direct medical costs, adaptative costs and social allowance
in case of blindness. RESULTS: Rate of visual acuity improve-
ment: Lucentis as ﬁrst line agent is signiﬁcantly more effective
(p < 0.001), providing greater treatment success rate of visual
acuity improvement than usual care (48.8% versus 33.9.1%).
Direct medical costs is 9123 Euros over 1 year for Lucentis
compared to 7604 Euros for usual care.Mean cost-effectiveness is
18721 Euros /success for Lucentis versus 22543 Euros/success for
usual care (p < 0.001). Rate of legal blindness avoided: Lucentis as
ﬁrst line agent is signiﬁcantlymore effective (p < 0.001), providing
greater treatment success rate of legal blindness avoided than
usual care (99.6% versus 93.1%). Direct medical costs is 10493
Euros over 1 year for Lucentis compared to 8016 Euros for usual
care. Mean cost-effectiveness is 10526 Euros /legal blindness
avoided for Lucentis versus 8607 Euros/legal blindness avoided
for usual care.CONCLUSION:Lucentis signiﬁcantly improve the
rate of visual acuity improvement and reduces the rate of legal
blindness. Lucentis is signiﬁcantly more cost-effective than usual
care in term of visual acuity improvement.
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OBJECTIVES:To compare the lifetime costs of complications due
to posterior capsule opaciﬁcation after cataract surgery in three
types of IOLs, namely two hydrophobic lenses SA60AT, AR40E
and one hydrophilic lens the XL-Stabi. METHODS: Costs were
estimated from the results of a retrospective study of patients who
underwent cataract surgery in 2001 and 2002 as well as from data
in the literature. Data were analysed after a minimum of 3 years
post-surgery using Kaplan-Meier survival curve analysis with the
end event being time to Nd:Yag laser capsulotomy. Costs were
calculated using two methods of extrapolation. The economic
perspectivewas that of the French Sickness Fund.RESULTS:After
3 years of follow-up, the percentage of patients who had under-
gone Nd:Yag laser capsulotomy was 12.0% with the SA60AT,
25.2% with the AR40E and 51.0% with the XL-Stabi lenses
(P < 0.001). The total cost of capsulotomy and management of
complications per patient lifetimewas estimated to be 142.6 Euros
for SA60AT, 273.4 Euros for AR40E ad 347.1 Euros for XL-Stabi
using the ﬁrst method of extrapolation, while using the second
method of extrapolation, the costs were 242.8, 317.6 and 347.2
Euros, respectively. CONCLUSION: Lower costs for cataract
surgery and management of related complications were observed
with the SA60AT and AR40E IOL’s with the lowest overall costs
being observed in the SA60AT lens.
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OBJECTIVES: Whilst the sight-restoring effects of surgery in
patients with severe bilateral cataract are obvious, there has been
a signiﬁcant trend over the last two decades of performing cata-
ract surgery at an increasingly earlier stage with a rising propor-
tion having 6/12 vision or better at the time of listing. In these
circumstances, the cost-effectiveness of surgery is open to ques-
tion. Therefore, this study evaluated the cost-effectiveness of
ﬁrst-eye cataract surgery compared to no surgery from a Health
Service and Personal Social Services perspective. METHODS: An
economic evaluation was undertaken alongside a randomised
controlled trial of ﬁrst-eye cataract surgery in secondary care
ophthalmology clinics. A total of 306 women over 70 years old
with bilateral cataracts were randomised to cataract surgery
(expedited, approximately 4 weeks) or control (routine, 12
months wait). Seventy-ﬁve percent of participants had baseline
acuity of 6/12 or better. Health and social service contacts were
collected at individual patient level from diaries ascertained at 3
and 9 months via telephone interviews, and at 6 and 12 months
via face-to-face interviews. Outcomes included falls and Quality
Adjusted Life Years (QALYs). RESULTS: The mean difference in
cost between the operated and control group was 2004 (boot-
strapped)(95% CI 1363 to 2833, p < 0.001) over one year
(UK  2004). However, those in the operated group experi-
enced, on average, 0.456 fewer falls, representing an incremental
cost per fall prevented of4390. The bootstrapped mean gain in
QALYs per patient was 0.056 (95% CI 0.006 to 0.108,
p < 0.001). The incremental cost utility ratio was 35,704,
above the currently accepted UK threshold level of willingness to
pay per QALY of30,000. However, in a model of the costs and
beneﬁts over patients’ expected lifetime, the incremental cost per
QALY was 13,172, under conservative assumptions. CON-
CLUSION: First-eye cataract surgery, whilst cost-ineffective over
the trial period, appeared cost-effective over participants’
remaining lifetime.
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OBJECTIVES: After 45–50 years of age, the vast majority of
people have presbyopia, a loss of the ability to focus on near
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